Business Description
Inventiva S.A. is a French pharmaceutical company working to bring new oral medicines to patients suffering from serious liver, metabolic, and rare diseases. Its lead drug candidate, Lanifibranor, is currently being tested in a large Phase 3 clinical trial targeting adults with a progressive liver condition known as MASH, while a second compound, Odiparcil, is being developed for patients with a rare genetic disorder affecting the body's ability to break down certain sugars. The company, founded in 2011 and based in Daix, France, is also conducting early-stage research into a potential treatment for a life-threatening lung disease.
